Valuation: NEOVACS

Market Cap 4.09K 4.71K 3.83K 3.49K 6.57K 449K 6.67K 45.14K 17.59K 226K 17.69K 17.3K 751K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -232K -188K -172K -323K -22.08M -328K -2.22M -865K -11.09M -870K -851K -36.93M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%+1.76%+4.62%+14.41% 49.54B
-0.14%+6.10%+491.53%+584.43% 44.06B
-0.06%+11.16%+23.92%+81.63% 40.85B
-0.87%+5.92%+34.22%+9.95% 40.14B
-4.04%+8.72%+22.60%+48.00% 34.17B
-1.41%+3.81%+32.73%+123.68% 16.9B
+0.35%+4.44% - - 16.78B
-0.43%+1.13%+5.04%+20.83% 14B
+0.84%+21.46%+90.94%+32.60% 13.46B
Average -0.82%+6.97%+88.20%+114.44% 29.99B
Weighted average by Cap. -1.01%+6.51%+106.10%+136.92%

Financials

2023 2024
Net sales 533K 615K 500K 456K 857K 58.6M 870K 5.89M 2.29M 29.42M 2.31M 2.26M 98.01M 434K 500K 407K 371K 697K 47.67M 708K 4.79M 1.87M 23.94M 1.88M 1.84M 79.73M
Net income -8.74M -10.08M -8.2M -7.47M -14.05M -961M -14.27M -96.52M -37.61M -482M -37.83M -37M -1.61B -32.91M -37.93M -30.86M -28.11M -52.87M -3.62B -53.71M -363M -142M -1.82B -142M -139M -6.05B
Net Debt -237K -273K -222K -202K -380K -25.98M -386K -2.61M -1.02M -13.05M -1.02M -1M -43.45M -205K -236K -192K -175K -329K -22.53M -335K -2.26M -882K -11.31M -887K -868K -37.68M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-